Can teeth grow back? Where the Japanese tooth regrowth drug stands in 2026
In short: a Japanese antibody, TRG035, grows new teeth in mice and ferrets by releasing a natural ‘brake’ on tooth formation. In humans, a first trial tested its safety in 30 adult men; the company says it saw no problems, but no figures have been published and no tooth regrowth has been demonstrated. The next trial, which the Japanese drug agency finished reviewing in August 2026, will target children born without several teeth; the team hopes for a treatment around 2030, but that is only a hope. For a tooth lost in adulthood, the options are still an implant, a bridge or a denture, and no laser, oil or supplement makes a tooth grow back.
Updated 14 October 2026.
Why don't our teeth grow back?
A shark replaces its teeth throughout its life. We, like most mammals, only get two sets: baby teeth, then permanent teeth. Specialists call this diphyodonty (‘two dentitions’). A permanent tooth lost to decay, gum disease or an accident does not come back.
Yet nature may have left a door ajar. Katsu Takahashi's Japanese team studied people with supernumerary teeth, meaning extra teeth. According to the team, these teeth come from a third dentition: tooth buds, called tooth germs, that form next to the permanent teeth and then regress without ever erupting (Murashima-Suginami et al., 2021). The idea would therefore not be to create a tooth from nothing, but to wake up a dormant germ. It is an appealing idea, but still debated: a researcher at the University of Hong Kong called it ‘revolutionary and controversial’ (AFP, 2024).
USAG-1, the tooth brake
A tooth forms when cells exchange chemical messages. Two ‘messaging systems’ are essential: those biologists call BMP and Wnt. A protein, USAG-1, slows down both systems. In mice, when the gene that makes USAG-1 is switched off, extra teeth appear (Kyoto University, 2021).
A gene is a ‘recipe’ written in our DNA, which the cell reads to make a protein. The Japanese team's idea: rather than touching the gene, neutralise the USAG-1 protein with a drug, to release the brake where a tooth germ is waiting.
The Japanese drug: where do things really stand?
An antibody that releases the brake
TRG035 is a monoclonal antibody: a laboratory-made protein, always identical, that latches onto a single target to neutralise it, here the USAG-1 protein. It is humanised, meaning modified to resemble a human antibody and be better tolerated. It is being developed by Toregem BioPharma, a young company founded in 2020 in Kyoto, spun off from Kyoto University and co-founded by Katsu Takahashi.
One detail mattered a lot: antibodies that blocked USAG-1 on both pathways (BMP and Wnt) caused birth and survival problems in mice. An antibody that blocks only the BMP pathway was enough to grow teeth, without these problems (Kyoto University, 2021).
The timeline
| Date | Milestone | What it proves |
|---|---|---|
| February 2021 | Publication in Science Advances: a single injection grows a whole tooth in mice born without certain teeth; in ferrets, an extra incisor appears | Efficacy in animals only (Murashima-Suginami et al., 2021) |
| 2019-2021 | Trials in beagle dogs born without teeth, described in a Japanese grant report | Animals, not published in a scientific journal |
| Autumn 2024 | Start of the first human trial (phase 1) at Kyoto University Hospital | It tests safety, not efficacy |
| September 2025 | Orphan drug status in Japan for severe tooth agenesis | An administrative status supporting rare diseases |
| November 2025 | Toregem announces that ‘safety has been confirmed’ | No figures published (Toregem, 2025b) |
| 17 August 2026 | The Japanese drug agency finishes reviewing the phase 2a trial in children | Ethics committee approval still pending; no start date (Toregem, 2026) |
| ‘Around 2030’ | Hoped-for availability | A statement to the press, not an official commitment |
The first human trial, in detail
According to the official Japanese clinical trial registry, this phase 1 enrolled up to 30 healthy men aged 30 to 64 who were missing at least one molar (jRCT, 2024). Each received a single infusion of TRG035 or a placebo, at increasing doses from one group to the next. The aim: to check that the product is well tolerated and see how it behaves in the body.
The registry lists the trial as completed, but no results have been posted there, and no scientific publication had appeared as of 14 October 2026. So we do not know whether a tooth started to grow in any participant. Katsu Takahashi told AFP he would be ‘over the moon’ if that happened (AFP, 2024), which makes it clear that this was not the trial's objective.
Who is it for first? Children born without teeth
The first target group is not the adult who has lost a molar, but the child with tooth agenesis: one or more teeth never formed. Specialists distinguish:
- hypodontia: fewer than six missing teeth, excluding wisdom teeth;
- oligodontia: six or more permanent teeth missing from birth;
- anodontia: absence of all teeth, very rare.
Agenesis is more common than you might think: a meta-analysis of 93 studies found it in 6.4% of people, and about 7% in Europe, slightly more often in women (Khalaf et al., 2014). Most often only one or two teeth are missing: mainly the lower second premolar and the upper lateral incisor. Severe forms (oligodontia) affect about 0.14% of patients (Modafferi et al., 2025). They are often genetic in origin (WNT10A, PAX9, MSX1, EDA genes…), sometimes as part of ectodermal dysplasia, a group of inherited conditions affecting the teeth, hair, skin and sweat glands.
This makes sense: the mice in which the drug worked carried gene defects (EDA, Msx1, Runx2), some of which also cause agenesis in humans. Phase 2a, the first trial designed to look for a real effect and the right dose in patients, will target children with severe agenesis. The 2024 plan mentioned children aged 2 to 7 missing at least four permanent teeth (AMED et al., 2024); the trade press mentions 24 children (Dentistry, 2026).
What about a tooth lost in adulthood?
This is the question everyone asks, and the honest answer is: not for a long time, and perhaps never with this drug.
- No regrowth has been demonstrated in humans.
- In ferrets, the antibody produced an extra tooth in a normal animal, not a lost tooth growing back.
- Toregem lists among its long-term goals teeth lost after birth and the ‘oral frailty’ of older people, with no data at this stage (Toregem, 2025a).
Even if all goes well, there will still need to be an efficacy trial in children, then further trials in adults, before any approval, first in Japan, then possibly in Europe.
Other avenues of research
| Avenue | What has been shown | Level of evidence |
|---|---|---|
| Bioengineered tooth (Takashi Tsuji's team, Japan) | A tooth germ reconstructed in the laboratory, then grafted into the jaw, produces a tooth that erupts, chews and responds to stimuli (Ikeda et al., 2009); in dogs, using their own cells (Ono et al., 2017) | Mice, dogs |
| Tooth organoids in gel (King's College London) | Dental cells from mouse embryos, cultured for 8 days in a hydrogel (a water-filled gel that acts as a scaffold), start forming a tooth (Zhang et al., 2024). No complete tooth, no graft | Cells in culture |
| Pulp stem cells | The pulp (the ‘nerve’ of the tooth) contains cells able to rebuild dentine. In children whose still-immature permanent tooth had lost its pulp after an injury, a graft of cells from their own baby teeth regenerated the pulp (Xuan et al., 2018) | Randomised trial in 40 children, inside an existing tooth |
| Low-level laser | More dentine produced inside the tooth in rats (Arany et al., 2014) | Animals; does not make a tooth grow back |
In 2025, media headlines claimed that British researchers had ‘grown a tooth in the lab’. In reality, the study described the very earliest stages of tooth formation, using mouse cells, in a culture dish (King's College London, 2025).
Beware of promises to ‘regrow teeth’
Online you will find toothpastes, oils, supplements and lasers ‘that regenerate teeth’. Here is what is true and what is not.
- Remineralisation exists, but it does not rebuild a tooth. Acids from dental plaque dissolve minerals from the enamel; saliva and fluoride put them back. At the white spot stage (early decay), the process can be stopped or even reversed. But a cavity is permanent damage that must be treated by a dentist (NIDCR, 2025).
- Fluoride works. A toothpaste with 1,000-1,500 ppm fluoride reduces decay; this is some of the strongest evidence in dental prevention (Walsh et al., 2019). In Belgium, the Superior Health Council recommends a toothpaste with 1,450 ppm from age 6, twice a day (SHC, 2021).
- Hydroxyapatite (the mineral in enamel, added to some toothpastes) did no worse than a fluoride toothpaste at preventing decay in an 18-month trial funded by the manufacturer (Paszynska et al., 2023). That is a single trial, against the dozens of studies supporting fluoride. And it protects; it does not regrow anything.
- Oil pulling (swishing coconut oil around the mouth) is not recommended by the American Dental Association: no reliable study shows an effect on decay (ADA, n.d.).
- ‘Regenerating’ supplements and lasers: no study shows that a supplement or laser regrows a tooth or lost enamel.
Today, what can you do when a tooth is missing?
The three options
- An implant: a titanium screw placed in the jawbone, which holds a crown. It does not affect the neighbouring teeth, but requires surgery and enough bone.
- A bridge: a false tooth attached to the neighbouring teeth, bonded or cemented.
- A removable denture: an appliance you take out, partial or complete.
Your dentist will help you choose based on the location, the condition of the neighbouring teeth, the available bone and your budget. Always ask for a written quote before an implant: its price varies widely and it is rarely reimbursed.
What NIHDI reimburses
- From age 70: insurance covers two implants to stabilise a complete lower denture, subject to conditions (NIHDI, 2014).
- Under 19, with at least four permanent teeth missing from birth (excluding wisdom teeth and lateral incisors): since 1 July 2024, a bonded bridge or a metal-framework partial denture is reimbursed, with no extra charge for the patient (NIHDI, n.d.).
- Removable dentures are partly reimbursed depending on age and situation; your health insurance fund can tell you more.
And if you do nothing?
A missing tooth is not just a cosmetic issue. After a molar or premolar is extracted, the alveolar bone (the part of the jaw that holds the teeth) lost on average half its width in one year in a study of 46 patients, mostly in the first three months (Schropp et al., 2003); this varies from person to person and can make placing an implant later more difficult. Neighbouring teeth and the opposing tooth can also shift, usually by a few millimetres over several years (Petridis et al., 2010). Nothing urgent in most cases, but a reason to talk to your dentist before too long.
‘Can you actually regrow teeth?’, The Bentist (Dr Ben Winters, orthodontist), August 2026.
Going further: why a drug takes so long
A new drug goes through several stages, each of which can take years:
- Preclinical studies: in the laboratory and in animals. For TRG035, this is done (mice, ferrets, dogs).
- Phase 1: a few dozen volunteers, to check safety and the tolerated dose. Done for TRG035; results not published.
- Phase 2: a few dozen to a few hundred patients, to see whether the product works and at what dose. This is the next step.
- Phase 3: a large comparative trial, to confirm efficacy and detect rarer side effects.
- Approval: in Japan, by the Ministry of Health after assessment by the PMDA; in Europe, by the European Commission after assessment by the European Medicines Agency (EMA). Reimbursement in Belgium is then decided by NIHDI.
Many promising drugs fail in phase 2 or 3. Orphan drug status, granted to treatments for rare diseases, can speed up some procedures, but does not exempt a drug from proving its efficacy. A date like ‘2030’ is therefore a goal, not a promise.
Test yourself
Sources
AFP. (2024, December 13). Smile, no dentures needed: Japanese researchers test pioneering drug to regrow teeth. Malay Mail. https://www.malaymail.com/amp/news/life/2024/12/13/smile-no-dentures-needed-japanese-researchers-test-pioneering-drug-to-regrow-teeth/159719
AMED, Kitano Hospital, Kyoto University Hospital, & Toregem BioPharma. (2024, May 3). Press release: launch of the first-in-human trial of TRG035 [in Japanese]. https://www.amed.go.jp/news/seika/files/000127493.pdf
American Dental Association. (n.d.). Oil pulling. MouthHealthy. https://www.mouthhealthy.org/all-topics-a-z/oil-pulling
Arany, P. R., Cho, A., Hunt, T. D., Sidhu, G., Shin, K., Hahm, E., Huang, G. X., Weaver, J., Chen, A. C.-H., Padwa, B. L., Hamblin, M. R., Barcellos-Hoff, M. H., Kulkarni, A. B., & Mooney, D. J. (2014). Photoactivation of endogenous latent transforming growth factor–β1 directs dental stem cell differentiation for regeneration. Science Translational Medicine, 6(238), 238ra69. https://doi.org/10.1126/scitranslmed.3008234
Dentistry. (2026, August 18). Tooth regrowth drug trial planned for 24 children in Japan. https://dentistry.co.uk/2026/08/18/tooth-regrowth-drug-trial-planned-for-24-children-in-japan/
Ikeda, E., Morita, R., Nakao, K., Ishida, K., Nakamura, T., Takano-Yamamoto, T., Ogawa, M., Mizuno, M., Kasugai, S., & Tsuji, T. (2009). Fully functional bioengineered tooth replacement as an organ replacement therapy. Proceedings of the National Academy of Sciences, 106(32), 13475–13480. https://doi.org/10.1073/pnas.0902944106
Japan Registry of Clinical Trials. (2024). jRCT2051240154: single-dose phase I trial of TRG035 in healthy adults [updated October 3, 2025]. https://jrct.mhlw.go.jp/en-latest-detail/jRCT2051240154
Khalaf, K., Miskelly, J., Voge, E., & Macfarlane, T. V. (2014). Prevalence of hypodontia and associated factors: A systematic review and meta-analysis. Journal of Orthodontics, 41(4), 299–316. https://doi.org/10.1179/1465313314Y.0000000116
King's College London. (2025, April 14). Lab-grown teeth might become an alternative to fillings following research breakthrough. https://www.kcl.ac.uk/news/lab-grown-teeth-might-become-an-alternative-to-fillings-following-research-breakthrough
Kyoto University. (2021, March 31). New drug to regenerate lost teeth. https://www.kyoto-u.ac.jp/en/research-news/2021-03-31
Modafferi, C., Tucci, I., Bogliardi, F. M., Gimondo, E., Chiurazzi, P., Tabolacci, E., & Grippaudo, C. (2025). Genetic aspects of tooth agenesis. Genes, 16(5), 582. https://doi.org/10.3390/genes16050582
Murashima-Suginami, A., Kiso, H., Tokita, Y., Mihara, E., Nambu, Y., Uozumi, R., Tabata, Y., Bessho, K., Takagi, J., Sugai, M., & Takahashi, K. (2021). Anti–USAG-1 therapy for tooth regeneration through enhanced BMP signaling. Science Advances, 7(7), eabf1798. https://doi.org/10.1126/sciadv.abf1798
National Institute for Health and Disability Insurance. (2014). Règle interprétative : implants, article 6 § 5bis (70 ans et plus, prothèse complète inférieure). https://webappsa.riziv-inami.fgov.be/Nomen/fr/377764/pdf/19647
National Institute for Health and Disability Insurance. (n.d.). Restauration dentaire complexe : remboursement pour des patients atteints d'un cancer ou d'anodontie et/ou d'oligodontie. Retrieved October 14, 2026. https://www.inami.fgov.be/fr/professionnels/professionnels-de-la-sante/dentistes/prestations-prix-et-remboursement/restauration-dentaire-complexe-remboursement-pour-des-patients-atteints-d-un-cancer-ou-d-anodontie-et-ou-d-oligodontie
NIDCR. (2025). The tooth decay process: How to reverse it and avoid a cavity. National Institute of Dental and Craniofacial Research. https://nidcr.nih.gov/health-info/tooth-decay/more-info/tooth-decay-process
Ono, M., Oshima, M., Ogawa, M., Sonoyama, W., Hara, E. S., Oida, Y., Shinkawa, S., Nakajima, R., Mine, A., Hayano, S., Fukumoto, S., Kasugai, S., Yamaguchi, A., Tsuji, T., & Kuboki, T. (2017). Practical whole-tooth restoration utilizing autologous bioengineered tooth germ transplantation in a postnatal canine model. Scientific Reports, 7, 44522. https://doi.org/10.1038/srep44522
Paszynska, E., Pawinska, M., Enax, J., Meyer, F., Schulze zur Wiesche, E., May, T. W., Amaechi, B. T., Limeback, H., Hernik, A., Otulakowska-Skrzynska, J., Krahel, A., Kaminska, I., Lapinska-Antonczuk, J., Stokowska, E., & Gawriolek, M. (2023). Caries-preventing effect of a hydroxyapatite-toothpaste in adults: A 18-month double-blinded randomized clinical trial. Frontiers in Public Health, 11, 1199728. https://doi.org/10.3389/fpubh.2023.1199728
Petridis, H. P., Tsiggos, N., Michail, A., Kafantaris, S. N., Hatzikyriakos, A., & Kafantaris, N. M. (2010). Three-dimensional positional changes of teeth adjacent to posterior edentulous spaces in relation to age at time of tooth loss and elapsed time. European Journal of Prosthodontics and Restorative Dentistry, 18(2), 78–83.
Schropp, L., Wenzel, A., Kostopoulos, L., & Karring, T. (2003). Bone healing and soft tissue contour changes following single-tooth extraction: A clinical and radiographic 12-month prospective study. International Journal of Periodontics & Restorative Dentistry, 23(4), 313–323.
Superior Health Council. (2021, October 8). Un grain de riz ou un petit pois de dentifrice fluoré [Press release]. https://news.belgium.be/fr/node/27953/pdf
Toregem BioPharma. (2025a, September 29). TRG035 designated as an orphan drug [in Japanese]. https://toregem.co.jp/archives/7365
Toregem BioPharma. (2025b, November 27). Notification of receipt of response regarding pre-IND meeting with the US FDA. https://toregem.co.jp/en/english2025/wp-content/uploads/2025/12/20251127_Notification-of-receipt-of-response-regarding-Pre-IND-meeting-with-the-US-FDA.pdf.pdf
Toregem BioPharma. (2026, August 17). Completion of the PMDA review of the phase IIa clinical trial notification [in Japanese]. https://toregem.co.jp/archives/9765
Walsh, T., Worthington, H. V., Glenny, A.-M., Marinho, V. C. C., & Jeroncic, A. (2019). Fluoride toothpastes of different concentrations for preventing dental caries. Cochrane Database of Systematic Reviews, (3), CD007868. https://doi.org/10.1002/14651858.CD007868.pub3
Xuan, K., Li, B., Guo, H., Sun, W., Kou, X., He, X., Zhang, Y., Sun, J., Liu, A., Liao, L., Liu, S., Liu, W., Hu, C., Shi, S., & Jin, Y. (2018). Deciduous autologous tooth stem cells regenerate dental pulp after implantation into injured teeth. Science Translational Medicine, 10(455), eaaf3227. https://doi.org/10.1126/scitranslmed.aaf3227
Zhang, X., Contessi Negrini, N., Correia, R., Sharpe, P. T., Celiz, A. D., & Angelova Volponi, A. (2024). Generating tooth organoids using defined bioorthogonally cross-linked hydrogels. ACS Macro Letters, 13(12), 1620–1626. https://doi.org/10.1021/acsmacrolett.4c00520